Terns PharmaceuticalsTERN
TERN logo
Fair Value
US$98.57
Share price09 Dec
US$52.9546.3% undervalued intrinsic discount
Loading
1Y1,641.78%
7D0.038%

TERN: Positioned for Dominance – The Intrinsic Value of TERN-701 Points to $98.57

Author hasn't set their bio yet

Published
09 Dec 25
Views
69
Invested

Fair Value vs Share Price

US$98.57
vs US$52.9546.3% undervalued intrinsic discount
PastFuture-90m4b20182020202220242025202620282030Revenue US$4.1bEarnings US$636.8m
8.3k%
Revenue growth
15.4%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Terns Pharmaceuticals

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Flawless balance sheet with slight risk.

Market capUS$6.1b
PB6.1x
Estimated Growth72.5%
Dividend YieldN/A
Full analysis

CEO & management

Amy Burroughs
CEO
1.3yrs
CEO Tenure

A clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity.